The website of America’s Health Rankings provides comprehensive data on colorectal cancer screening in the United States. As of the latest data, 61.8% of adults aged 45-75 reported receiving one or more of the recommended colorectal cancer screening tests within the recommended time interval. These tests include blood stool tests within the past year, sigmoidoscopy within the past five years, colonoscopy within the past 10 years, stool DNA tests within the past three years, and virtual colonoscopy within the past five years or sigmoidoscopy within the past 10 years along with a blood stool test in the past year. The…
Author: Abhay Panchal
Geneoscopy and Adiso Therapeutics have entered into a strategic collaboration to use Geneoscopy’s stool-based transcriptome platform in a Phase II clinical trial of Adiso’s experimental treatment for inflammatory bowel disease (IBD), ADS051. ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation. Geneoscopy’s platform will be utilized to prospectively assess gene expression changes in stool samples from patients in the trial, with the aim of identifying likely treatment responders and providing a minimally invasive method to monitor for clinical remission. The global Phase II trial for ADS051 is set to begin recruitment next year. Adiso plans to…
Mainz Biomed N.V., a molecular genetics diagnostic company, has announced significant topline results from its eAArly DETECT U.S. clinical study. This multi-center feasibility study evaluated the integration of novel gene expression (mRNA) biomarkers into ColoAlert®, the company’s effective and user-friendly screening test for colorectal cancer (CRC), currently available in Europe and select international markets. The eAArly DETECT study demonstrated a remarkable sensitivity for colorectal cancer detection at 97% with a specificity of 97%, and an advanced adenoma sensitivity of 82%. These results not only confirm but also surpass those from the company’s European ColoFuture Clinical Study, which reported a colorectal…
Oshi Health, a virtual gastrointestinal clinic, has expanded its services to more employers through a partnership with Willis Towers Watson (WTW), an advisory, broking, and solutions company. This collaboration aims to offer WTW clients a comprehensive digestive health solution. Oshi Health provides employers with a virtual care model that delivers multidisciplinary care in partnership with local in-person providers. This approach is designed to accelerate the process of diagnosis, treatment, and symptom control for digestive health issues. In 2022, Oshi Health conducted pilot programs with several WTW employer clients, resulting in high member satisfaction, symptom improvement, and resolution. Following the success…
EndoQuest, a company specializing in endoluminal robotics technology, has successfully closed a $42 million C-1 preferred financing round. This round saw participation from existing investors CE Ventures Limited and McNair Interests Ltd., as well as new investor Puma Venture Capital LLC. Based in Houston, EndoQuest has developed a flexible robotics surgery system designed for minimally invasive procedures in the gastrointestinal tract and other endoluminal areas. This technology enables endoluminal and single-incision surgeries through natural body orifices or via a transumbilical incision. The company plans to use the newly acquired funds to expand its operations, which includes scaling up commercialization efforts,…
DiaCarta’s iColon Fecal Occult Blood Test, an over-the-counter product, has received FDA 510(k) clearance. This test enables early at-home detection of blood in stool, a key indicator of gastrointestinal disorders and colorectal cancer. It complements DiaCarta’s existing ColoScape test, which identifies colorectal cancer-associated mutations and methylation biomarkers in circulating blood to assess high-risk patients for colorectal cancer. Key Insights:
Dive deep with Prof. David C. Whitcomb, MD, PhD, Co-founder & Chief Scientific Officer at Ariel Precision Medicine, as he challenges the traditional germ theory and advocates for the adoption of precision medicine in healthcare. This insightful conversation is essential for anyone interested in the future of personalized healthcare and the role of genetics in medicine. Prof. Whitcomb is widely considered as the father of pancreatic genetics with the discovery that mutation in the trypsin gene caused hereditary pancreatitis. With 25+ years of continuous, NIH funding, he built one of the top genetics programs for digestive diseases. He says, the…
Gastro Health partnered with M.H. Razavi, MD, and the Endoscopy & Digestive Center of Woodbridge (Va.). The partnership marks the company’s seventh partnership in the state, according to a Dec. 1 news release from Gastro Health shared with Becker’s. Gastro Health’s footprint spans seven states: Florida, Alabama, Washington, Virginia, Ohio, Maryland and Massachusetts. The company has more than 400 physicians and 150 locations.
The study, involving three Italian research centers and the creator of the GI Genius intelligent endoscopy module, revealed significant advantages of computer-aided detection in identifying adenomas during colonoscopies. Key findings from the study include: These findings suggest that computer-aided polyp detection significantly outperforms traditional high-definition colonoscopy in several key areas, particularly in increasing the overall detection rates of adenomas and polyps, which are crucial for early cancer screening and prevention.
The article from HCP Live, authored by Patrick Campbell, highlights significant sex- and race-based disparities in colorectal cancer testing, particularly in diagnostic practices among patients with iron deficiency anemia and/or hematochezia. This analysis is based on data from the Veterans Health Administration, covering a 20-year period from 1999 to 2019. Key findings from the study include: Disparities in Diagnostic Testing: The study found that diagnostic testing rates with endoscopy among veterans aged 18 to 49 years with iron deficiency anemia (IDA) and/or hematochezia are low and vary significantly across demographic groups. Notably, Black veterans with IDA and Hispanic veterans with…